The Fund aims to achieve long term capital growth primarily through investment in a portfolio of equities issued by continental European companies and in derivatives, the underlying assets of which are equities issued by continental European companies.
Name | % Net Assets |
---|---|
Novartis | 5.5% |
Sanofi-Synthelabo | 4.9% |
Total SA | 4.1% |
Bayer | 3.3% |
Anheuser-Busch Inbev | 3.2% |
SAP | 2.7% |
Novo Nordisk A/S | 2.7% |
Unilever NV | 2.6% |
Teleperformance SA | 2.6% |
ING Groep N.V. | 2.4% |
Key | % Net Assets |
---|---|
Novartis | 5.5% |
Sanofi-Synthelabo | 4.9% |
Total SA | 4.1% |
Bayer | 3.3% |
Other | 82.2% |
Date | 03-Jan-2013 |
---|---|
NAV | 330.49p |
Currency | GBP |
Change | -0.40p |
% | -0.12% |
YTD change | 330.49p |
YTD % | n/a |
Fund Inception | 24/09/1986 |
---|---|
Fund Manager | Nigel Hankin |
TER | 1.62 (31-Dec-2011) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £100 |
Savings | £100 |
Charges | |
---|---|
Initial | 4.50% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.06 |
You are here: research